Q4 2024 Earnings Call Transcript February 20, 2025 Dynavax Technologies Corporation reports earnings inline with expectations ...

Life sciences investment firm Deep Track Capital is launching a board fight at Dynavax Technologies, pressing for new ...

Dynavax Technologies (NASDAQ:DVAX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by William Blair in a note issued to investors on Friday,RTT News reports. William Blair also issued ...

Citizens JMP raised the firm’s price target on Dynavax (DVAX) to $33 from $29 and keeps an Outperform rating on the shares. Dynavax reported ...

Full Year 2024 Results Key Financial Results Revenue: US$277.2m (up 19% from ...

During the last three months, 4 analysts shared their evaluations of Dynavax Technologies DVAX, revealing diverse outlooks from bullish to bearish. The following table encapsulates their recent ...

Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued a statement ...

HEPLISAV-B net product revenue is expected in the range of $305M to $325M Discover the Best Stocks and Maximize Your Portfolio: See what ...

Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NAS ...

As Dynavax's second-largest investor with a 13.5% stake, Deep Track describes itself as a loyal shareholder which believes in ...

Dynavax Technologies Corporation ( NASDAQ: DVAX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - ...